Immune Cell Infiltration Types as Biomarkers for the Recurrence Diagnosis and Prognosis of Bladder Cancer

References

• Messing EM. Why should we increase public awareness of bladder cancer, and how can we do it? Nat Clin Pract Urol. 2008;5(3):117–117. doi:10.1038/ncpuro1061.
   PubMedGoogle Scholar
• Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol. 2016;34(16):1935–1944. doi:10.1200/JCO.2015.64.4070.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Westhoff E, Wu X, Kiemeney LA, Lerner SP, Ye Y, Huang M, et al. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int J Cancer. 2018;142(9):1797–1804. doi:10.1002/ijc.31214.
   PubMed Web of Science ®Google Scholar
• Wang TW, Yuan H, Diao WL, Yang R, Zhao XZ, Guo HQ. Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence. BMC Urol. 2019;19(1):90. doi:10.1186/s12894-019-0530-0.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Tervahartiala M, Taimen P, Mirtti T, Koskinen I, Ecke T, Jalkanen S, et al. Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Sci Rep. 2017;7(1):12682. doi:10.1038/s41598-017-12892-5.
   Google Scholar
• Domingues P, González-Tablas M, Otero Á, Pascual D, Miranda D, Ruiz L, et al. Tumor infiltrating immune cells in gliomas and meningiomas. Brain Behav Immun. 2016;53:1–15. doi:10.1016/j.bbi.2015.07.019.
   PubMed Web of Science ®Google Scholar
• Klose CS, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17(7):765–774. doi:10.1038/ni.3489.
   PubMed Web of Science ®Google Scholar
• Tamborero D, Rubio-Perez C, Muiños F, Sabarinathan R, Piulats JM, Muntasell A, et al. A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations. Clin Cancer Res. 2018;24(15):3717–3728. doi:10.1158/1078-0432.CCR-17-3509.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75–94. doi:10.1016/j.eururo.2021.08.010.
   PubMed Web of Science ®Google Scholar
• Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: mining tens of millions of expression profiles–database and tools update. Nucleic Acids Res. 2007;35(Database issue):D760–5. (Database issue):doi:10.1093/nar/gkl887.
   PubMedGoogle Scholar
• Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, et al. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012;18(5):1323–1333. doi:10.1158/1078-0432.CCR-11-2271.
   PubMed Web of Science ®Google Scholar
• Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D. Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife. 2017;6:e26476. doi:10.7554/eLife.26476.
   PubMed Web of Science ®Google Scholar
• Wang Q, Liu X. Screening of feature genes in distinguishing different types of breast cancer using support vector machine. Onco Targets Ther. 2015;8:2311–2317. doi:10.2147/OTT.S85271.
   PubMed Web of Science ®Google Scholar
• Deist TM, Dankers F, Valdes G, Wijsman R, Hsu IC, Oberije C, et al. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers. Med Phys. 2018;45(7):3449–3459. doi:10.1002/mp.12967.
   PubMed Web of Science ®Google Scholar
• Lu X, Yang Y, Wu F, Gao M, Xu Y, Zhang Y, et al. Discriminative analysis of schizophrenia using support vector machine and recursive feature elimination on structural MRI images. Medicine. 2016;95(30):e3973. doi:10.1097/MD.0000000000003973.
   PubMed Web of Science ®Google Scholar
• Schwarzova L, Varchulova Novakova Z, Danisovic L, Ziaran S. Molecular classification of urothelial bladder carcinoma. Mol Biol Rep. 2023;50(9):7867–7877. doi:10.1007/s11033-023-08689-7.
   PubMed Web of Science ®Google Scholar
• Zapf A, Brunner E, Konietschke F. A wild bootstrap approach for the selection of biomarkers in early diagnostic trials. BMC Med Res Methodol. 2015;15(1):43. doi:10.1186/s12874-015-0025-y.
   PubMedGoogle Scholar
• Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S + to analyze and compare ROC curves. BMC Bioinformatics. 2011;12(1):77. doi:10.1186/1471-2105-12-77.
   PubMed Web of Science ®Google Scholar
• Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. Biom J. 2010;52(1):70–84. doi:10.1002/bimj.200900028.
   PubMed Web of Science ®Google Scholar
• Tibshirani R. The lasso method for variable selection in the Cox model. Statist Med. 1997;16(4):385–395. doi:10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang Y, Hang B, Zou X, Mao JH. A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 2016;7(34):55343–55351. doi:10.18632/oncotarget.10533.
   PubMedGoogle Scholar
• Anderson WI, Schlafer DH, Vesely KR. Thyroid follicular carcinoma with pulmonary metastases in a beaver (Castor canadensis). J Wildl Dis. 1989;25(4):599–600. doi:10.7589/0090-3558-25.4.599.
   PubMed Web of Science ®Google Scholar
• Eng KH, Schiller E, Morrell K. On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve. Oncotarget. 2015;6(34):36308–36318. doi:10.18632/oncotarget.6121.
   PubMedGoogle Scholar
• Shan S, Chen W, Jia JD. Transcriptome analysis revealed a highly connected gene module associated with cirrhosis to hepatocellular carcinoma development. Front Genet. 2019;10:305. doi:10.3389/fgene.2019.00305.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47–e47. doi:10.1093/nar/gkv007.
   PubMed Web of Science ®Google Scholar
• Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol. 2010;28(4):401–408. doi:10.1016/j.urolonc.2009.04.019.
   PubMed Web of Science ®Google Scholar
• Bolenz C, Lotan Y. Translational research in bladder cancer: from molecular pathogenesis to useful tissue biomarkers. Cancer Biol Ther. 2010;10(5):407–415. doi:10.4161/cbt.10.5.13022.
   PubMed Web of Science ®Google Scholar
• McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, et al. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010;28(4):429–440. doi:10.1016/j.urolonc.2010.04.008.
   PubMed Web of Science ®Google Scholar
• Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10(1):31–43.
   PubMedGoogle Scholar
• Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174. doi:10.1016/j.redox.2019.101174.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick JM, West AB, Butler MR, Lane V, O'Flynn JD. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. J Urol. 1986;135(5):920–922. doi:10.1016/s0022-5347(17)45923-4.
   PubMed Web of Science ®Google Scholar
• Wang J, Li D, Cang H, Guo B. Crosstalk between cancer and immune cells: role of tumor-associated macrophages in the tumor microenvironment. Cancer Med. 2019;8(10):4709–4721. doi:10.1002/cam4.2327.
   PubMed Web of Science ®Google Scholar
• Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, et al. Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical cystectomy: a multicenter experience. Medicine. 2015;94(42):e1861. doi:10.1097/MD.0000000000001861.
   PubMed Web of Science ®Google Scholar
• Cantiello F, Russo GI, Vartolomei MD, Farhan ARA, Terracciano D, Musi G, et al. Systemic inflammatory markers and oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Eur Urol Oncol. 2018;1(5):403–410. doi:10.1016/j.euo.2018.06.006.
   PubMed Web of Science ®Google Scholar
• Ferro M, Di Mauro M, Cimino S, Morgia G, Lucarelli G, Abu Farhan AR, et al. Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Transl Androl Urol. 2021;10(2):626–635. doi:10.21037/tau-20-1272.
   PubMed Web of Science ®Google Scholar
• Wołącewicz M, Hrynkiewicz R, Grywalska E, Suchojad T, Leksowski T, Roliński J, et al. Immunotherapy in bladder cancer: current methods and future perspectives. Cancers. 2020;12(5):1181. doi:10.3390/cancers12051181.
   PubMed Web of Science ®Google Scholar
• Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615–625. doi:10.1038/s41585-018-0055-4.
   PubMed Web of Science ®Google Scholar
• Ward Grados DF, Ahmadi H, Griffith TS, Warlick CA. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol Invest. 2022;51(8):2226–2251. doi:10.1080/08820139.2022.2118606.
   PubMed Web of Science ®Google Scholar
• Pichler R, Fritz J, Zavadil C, Schäfer G, Culig Z, Brunner A. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget. 2016;7(26):39916–39930. doi:10.18632/oncotarget.9537.
   PubMed Web of Science ®Google Scholar
• Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol. 2009;55(6):1386–1395. doi:10.1016/j.eururo.2009.01.040.
   PubMed Web of Science ®Google Scholar
• Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, et al. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology. 2001;57(4):617–621. doi:10.1016/s0090-4295(01)00921-9.
   PubMed Web of Science ®Google Scholar
• Ferro M, Di Lorenzo G, Vartolomei MD, Bruzzese D, Cantiello F, Lucarelli G, et al. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. World J Urol. 2020;38(1):143–150. doi:10.1007/s00345-019-02754-2.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Powles T, Vogelzang NJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev. 2017;54:58–67. doi:10.1016/j.ctrv.2017.01.007.
   PubMed Web of Science ®Google Scholar
• Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, et al. Differential expression of PD-L1 in high grade T1 vs muscle invasive bladder carcinoma and its prognostic implications. J Urol. 2017;198(4):817–823. doi:10.1016/j.juro.2017.04.102.
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell. 2016;29(3):285–296. doi:10.1016/j.ccell.2016.02.004.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571. doi:10.1038/nature13954.
   PubMed Web of Science ®Google Scholar
• Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104(10):3967–3972. doi:10.1073/pnas.0611618104.
   PubMed Web of Science ®Google Scholar
• Dyugay IA, Lukyanov DK, Turchaninova MA, Serebrovskaya EO, Bryushkova EA, Zaretsky AR, et al. Accounting for B-cell behavior and sampling bias predicts anti-PD-L1 response in bladder cancer. Cancer Immunol Res. 2022;10(3):343–353. doi:10.1158/2326-6066.CIR-21-0489.
   PubMed Web of Science ®Google Scholar
• Wahlin S, Nodin B, Leandersson K, Boman K, Jirström K. Clinical impact of T cells, B cells and the PD-1/PD-L1 pathway in muscle invasive bladder cancer: a comparative study of transurethral resection and cystectomy specimens. Oncoimmunology. 2019;8(11):e1644108. doi:10.1080/2162402X.2019.1644108.
   PubMed Web of Science ®Google Scholar
• Zhang C, Shen L, Qi F, Wang J, Luo J. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma. J Cell Physiol. 2020;235(4):3849–3863. doi:10.1002/jcp.29279.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liu Y, Chen P, Shi X, Liu Y, Shi L, et al. Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer. Bioengineered. 2021;12(1):4946–4961. doi:10.1080/21655979.2021.1962485.
   PubMed Web of Science ®Google Scholar
• Li X, Feng J, Sun Y, Li X. An exploration of the tumor microenvironment identified a novel five-gene model for predicting outcomes in bladder cancer. Front Oncol. 2021;11:642527. doi:10.3389/fonc.2021.642527.
   PubMed Web of Science ®Google Scholar
• Busetto GM, Ferro M, Del Giudice F, Antonini G, Chung BI, Sperduti I, et al. The prognostic role of circulating tumor cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2017;15(4):e661–e6. doi:10.1016/j.clgc.2017.01.011.
   PubMed Web of Science ®Google Scholar
• Luo C, Lei M, Zhang Y, Zhang Q, Li L, Lian J, et al. Systematic construction and validation of an immune prognostic model for lung adenocarcinoma. J Cell Mol Med. 2020;24(2):1233–1244. doi:10.1111/jcmm.14719.
   PubMed Web of Science ®Google Scholar
• Zhou YX, Wang C, Mao LW, Wang YL, Xia LQ, Zhao W, et al. Long noncoding RNA HOTAIR mediates the estrogen-induced metastasis of endometrial cancer cells via the miR-646/NPM1 axis. Am J Physiol Cell Physiol. 2018;314(6):C690–c701. doi:10.1152/ajpcell.00222.2017.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu T, Cheng Y, Bai Y, Liang G. Immune cell infiltration as a biomarker for the diagnosis and prognosis of digestive system cancer. Cancer Sci. 2019;110(12):3639–3649. doi:10.1111/cas.14216.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu S, Guo Q, Zhang S, Zhao Y, Wang H, et al. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway. Int J Biol Sci. 2019;15(7):1488–1499. doi:10.7150/ijbs.32718.
   PubMed Web of Science ®Google Scholar
• Cao R, Yuan L, Ma B, Wang G, Tian Y. Immune-related long non-coding RNA signature identified prognosis and immunotherapeutic efficiency in bladder cancer (BLCA). Cancer Cell Int. 2020;20(1):276. doi:10.1186/s12935-020-01362-0.
   PubMed Web of Science ®Google Scholar